Description: Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Home Page: www.endo.com
0Y5F Technical Analysis
Minerva House
Dublin,
4
Ireland
Phone:
353 1 268 2000
Officers
| Name | Title |
|---|---|
| Mr. Blaise A. Coleman | President, CEO & Director |
| Mr. Matthew Joseph Maletta | Executive VP, Chief Legal Officer & Company Secretary |
| Dr. James Patrick Tursi M.D. | Executive Vice President of Global Research & Development |
| Mr. Mark T. Bradley | Executive VP & CFO |
| Frank B. Raciti | VP, Controller & Chief Accounting Officer |
| Ms. Cheryl Stouch | Senior VP of Information Technology & Chief Information Officer |
| Ms. Laure E. Park | Senior Vice President of Investor Relations & Corporate Affairs |
| Ms. Susan Williamson | Senior VP & Chief Compliance Officer |
| Ms. Tracy Basso | Chief Human Resources Officer |
| Mr. Patrick A. Barry | Executive VP & President of Global Commercial Operations |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2931 |